<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnosis of primary aldosteronism</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnosis of primary aldosteronism</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diagnosis of primary aldosteronism</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William F Young, Jr, MD, MSc</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynnette K Nieman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Nonsuppressible (primary) hypersecretion of aldosterone is an underdiagnosed cause of hypertension. The classic presenting signs of primary aldosteronism are hypertension and hypokalemia, but potassium levels are frequently normal in modern-day series of primary aldosteronism. The most common subtypes of primary aldosteronism are:</p><p class="bulletIndent1"><span class="glyph">●</span>Unilateral aldosterone-producing adenomas (APAs; ≥10 mm) or aldosterone-producing micronodules (&lt;10 mm)</p><p class="bulletIndent1"><span class="glyph">●</span>Bilateral idiopathic hyperaldosteronism (IHA; bilateral adrenal hyperplasia)</p><p></p><p>Less common forms include:</p><p class="bulletIndent1"><span class="glyph">●</span>Familial hyperaldosteronism (FH) types I to IV and primary aldosteronism with seizures and neurologic abnormalities (PASNA) (see  <a class="medical medical_review" href="/d/html/122.html" rel="external">"Familial hyperaldosteronism"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Unilateral hyperplasia or primary adrenal hyperplasia (caused by micronodular or macronodular hyperplasia of the zona glomerulosa of one adrenal gland)</p><p class="bulletIndent1"><span class="glyph">●</span>Pure aldosterone-producing adrenocortical carcinomas</p><p class="bulletIndent1"><span class="glyph">●</span>Ectopic aldosterone-producing tumors</p><p></p><p>The diagnosis of primary aldosteronism will be reviewed here. The clinical manifestations and treatment of this disorder are discussed separately. (See  <a class="medical medical_review" href="/d/html/140.html" rel="external">"Pathophysiology and clinical features of primary aldosteronism"</a> and  <a class="medical medical_review" href="/d/html/141.html" rel="external">"Treatment of primary aldosteronism"</a>.)</p><p class="headingAnchor" id="H847069215"><span class="h1">BACKGROUND</span></p><p class="headingAnchor" id="H2048415590"><span class="h2">Prevalence of primary aldosteronism</span><span class="headingEndMark"> — </span>Older studies suggested a prevalence of primary aldosteronism of less than 1 percent of patients with hypertension. However, subsequent studies document a considerably higher prevalence [<a href="#rid1">1-4</a>]. In a retrospective, multicenter review, more widespread measurement of the plasma aldosterone concentration (PAC) and plasma renin activity (PRA) as a case-detection test in patients with hypertension resulted in marked increases (1.3- to 6.3-fold) in the annual detection rate of primary aldosteronism and in the proportion of patients with hypertension in whom primary aldosteronism was detected (1 to 2 percent before screening versus 5 to 10 percent after screening) [<a href="#rid1">1,3,5</a>]. </p><p>In addition, in a cross-sectional study, a continuum of renin-independent aldosterone production was evident within every blood pressure category; greater renin-independent aldosterone production was associated with higher blood pressure, greater kaliuresis, and lower serum potassium levels [<a href="#rid6">6</a>]. The adjusted prevalence estimates for primary aldosteronism were 11.3 percent in patients with normotension and 15.7, 21.6, and 22 percent in those with stage 1, stage 2, and resistant hypertension, respectively. Thus, primary aldosteronism appears to be highly prevalent and underrecognized [<a href="#rid6">6</a>]. </p><p class="headingAnchor" id="H2"><span class="h2">Variable presentation</span><span class="headingEndMark"> — </span>The presence of primary mineralocorticoid excess should be suspected in any patient with the triad of hypertension, unexplained hypokalemia, and metabolic alkalosis [<a href="#rid7">7-9</a>]. However, most patients with primary mineralocorticoid excess have normokalemia and, rarely, some have hypokalemia but normotension (primarily young adult females).</p><p>An estimated 9 to 37 percent of patients with primary aldosteronism have hypokalemia [<a href="#rid1">1,5</a>]. This reduction in prevalence likely reflects earlier diagnosis as more patients with hypertension are being screened for primary aldosteronism. (See  <a class="medical medical_review" href="/d/html/140.html" rel="external">"Pathophysiology and clinical features of primary aldosteronism", section on 'Hypokalemia: An inconsistent finding'</a>.)</p><p>A few patients with primary aldosteronism have hypokalemia but a normal systemic blood pressure [<a href="#rid10">10</a>]. In such patients, surreptitious vomiting, diuretic therapy, and Bartter syndrome should be excluded; these disorders lead to secondary hyperaldosteronism with increased PRA and plasma renin concentration (PRC) rather than the suppressed PRA and PRC values evident in primary aldosteronism. (See <a class="local">'Other causes of hypertension and hypokalemia'</a> below.)</p><p>Patients with the rare genetic disorder glucocorticoid-remediable aldosteronism (GRA) generally present with normokalemia. Important physiologic differences between GRA and other forms of hyperaldosteronism could account for the lesser likelihood of potassium wasting. (See  <a class="medical medical_review" href="/d/html/122.html" rel="external">"Familial hyperaldosteronism"</a>.)</p><p class="headingAnchor" id="H2697328494"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Identifying primary aldosteronism is important because of its high prevalence and association with increased cardiovascular morbidity and mortality relative to primary hypertension with the same degree of blood pressure elevation [<a href="#rid11">11</a>]. In patients diagnosed with primary aldosteronism, treatment of the mineralocorticoid excess results in reversal or improvement of hypertension and remediation of the increased cardiovascular risk. (See  <a class="medical medical_review" href="/d/html/141.html" rel="external">"Treatment of primary aldosteronism"</a>.)</p><p>The diagnosis of primary aldosteronism includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Case-detection testing</strong> – Testing should be performed in patient groups with a relatively high prevalence of primary aldosteronism (see <a class="local">'Patient selection'</a> below). Measurements of the plasma renin activity (PRA; <strong>or</strong> plasma renin concentration [PRC]) and plasma aldosterone concentration (PAC) are obtained in the morning in a seated ambulatory patient. (See <a class="local">'Case detection'</a> below.)</p><p></p><p class="bulletIndent1">The initial evaluation should consist of documenting that the PRA or PRC is suppressed (PRA &lt;1 ng/mL/hour; PRC less than the lower limit of reference range) and that the PAC is inappropriately high for the PRA (typically &gt;10 ng/dL [277 pmol/L])  (<a class="graphic graphic_algorithm graphicRef111376" href="/d/graphic/111376.html" rel="external">algorithm 1</a>). (See <a class="local">'Initial testing'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Case confirmation</strong> – In most patients, an elevated PAC with a low renin level is not sufficient to establish the diagnosis of primary aldosteronism, which must be confirmed by demonstrating inappropriate aldosterone secretion with one of several tests.</p><p></p><p class="bulletIndent1">The <strong>exception</strong> to the requirement for confirmatory testing is the patient with <strong>all</strong> of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Spontaneous hypokalemia</p><p class="bulletIndent2"><span class="glyph">•</span>Suppressed PRA (&lt;1 ng/mL/hour) or PRC (below the lower limit of the reference range)</p><p class="bulletIndent2"><span class="glyph">•</span>PAC ≥20 ng/dL (555 pmol/L)</p><p></p><p class="bulletIndent1">In this clinical setting, no diagnosis other than primary aldosteronism can explain the findings. However, for all other patients, aldosterone suppression testing is needed. (See <a class="local">'Confirmation of the diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subtype classification</strong> – Once the diagnosis of primary aldosteronism has been established, a unilateral aldosterone-producing adenoma (APA), or rarely, carcinoma, must be distinguished from bilateral hyperplasia (idiopathic hyperaldosteronism [IHA]). This distinction is important since the treatment options are different for the two disorders. To differentiate APA from IHA, we employ the algorithm developed at the Mayo Clinic that uses adrenal computed tomography (CT) and adrenal vein sampling (AVS)  (<a class="graphic graphic_algorithm graphicRef76673" href="/d/graphic/76673.html" rel="external">algorithm 2</a>). (See <a class="local">'Subtype classification'</a> below.)</p><p></p><p class="headingAnchor" id="H2090724661"><span class="h1">CASE DETECTION</span><span class="headingEndMark"> — </span>Case-detection testing with measurement of plasma aldosterone concentration (PAC) and renin (plasma renin activity [PRA] or plasma renin concentration [PRC]) should be performed in patient groups with a relatively high prevalence of primary aldosteronism. As noted, the prevalence of primary aldosteronism in patients with hypertension is considerably higher than previously thought (see <a class="local">'Prevalence of primary aldosteronism'</a> above). In addition, more widespread testing has demonstrated that normokalemic, rather than hypokalemic, hypertension is the most common presentation of primary aldosteronism [<a href="#rid1">1,5,12,13</a>]. (See <a class="local">'Variable presentation'</a> above.)</p><p>Our approach outlined below is consistent with the Endocrine Society 2016 clinical practice guidelines [<a href="#rid5">5</a>]. Recommendations for the treatment of primary aldosteronism are reviewed separately. (See  <a class="medical medical_review" href="/d/html/141.html" rel="external">"Treatment of primary aldosteronism"</a>.)</p><p class="headingAnchor" id="H86977380"><span class="h2">Patient selection</span><span class="headingEndMark"> — </span>We suggest case-detection testing for primary aldosteronism in the following patients  (<a class="graphic graphic_algorithm graphicRef111376" data-inline-graphics="111376" href="/d/graphic/111376.html" rel="external">algorithm 1</a>) [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension and spontaneous or diuretic-induced hypokalemia</p><p></p><p>Patients with any of the following should undergo testing even if they have <strong>normokalemia</strong> (see  <a class="medical medical_review" href="/d/html/140.html" rel="external">"Pathophysiology and clinical features of primary aldosteronism", section on 'Cardiovascular risk'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Severe hypertension (&gt;150 mmHg systolic or &gt;100 mmHg diastolic) or drug-resistant hypertension (defined as suboptimally controlled hypertension on a three-drug program that includes an adrenergic inhibitor, vasodilator, and diuretic)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension with adrenal incidentaloma</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension with sleep apnea</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension and a family history of early-onset hypertension or cerebrovascular accident at a young age (&lt;40 years)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension and a first-degree relative with primary aldosteronism</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension and atrial fibrillation [<a href="#rid11">11,14</a>]</p><p></p><p>We do <strong>not</strong> recommend case-detection testing in older (eg, &gt;70 years of age) patients with normokalemia and mild hypertension or in patients in whom the diagnosis would not change management (eg, the older patient with hypertension that is easily controlled with a single drug). (See  <a class="medical medical_review" href="/d/html/3852.html" rel="external">"Overview of hypertension in adults", section on 'Definitions'</a> and  <a class="medical medical_review" href="/d/html/3862.html" rel="external">"Evaluation of secondary hypertension"</a>.)</p><p class="headingAnchor" id="H231433280"><span class="h3">Low rates of testing</span><span class="headingEndMark"> — </span>In spite of clinical guidelines that recommend testing in patient groups with a relatively high prevalence of primary aldosteronism (eg, treatment-resistant hypertension or hypertension with hypokalemia), this disorder remains underdiagnosed and untreated [<a href="#rid5">5,6,15</a>].</p><p>Clinical data indicate that testing for primary hyperaldosteronism is performed in only approximately 2 to 4 percent of patients meeting criteria for case-detection testing, including those with resistant hypertension and hypokalemia [<a href="#rid16">16-19</a>]. As an example, in a retrospective, multicenter cohort study of 269,010 United States veterans with apparent treatment-resistant hypertension, only 4277 patients (1.6 percent) underwent the recommended testing for primary aldosteronism [<a href="#rid16">16</a>]. Low testing rates were observed at all centers, and no improvements in testing frequency were seen over the 17 years of the study (2000 to 2017). Among those patients who were tested, higher rates of mineralocorticoid receptor antagonist use and better blood pressure control over time were observed.</p><p>This low rate of testing underscores the need for additional provider education about the importance of testing, the increased kidney and cardiovascular morbidity from mineralocorticoid excess, and the possibility of preventing this morbidity with appropriate treatment. (See  <a class="medical medical_review" href="/d/html/141.html" rel="external">"Treatment of primary aldosteronism", section on 'Treatment goals'</a>.)</p><p class="headingAnchor" id="H1832243811"><span class="h2">Initial testing</span><span class="headingEndMark"> — </span>The sequential evaluation of a patient with possible primary aldosteronism begins with paired measurement of the PAC and PRA <strong>or</strong> PRC [<a href="#rid7">7-9</a>]. Some clinicians calculate a PAC/PRA ratio as part of the case-detection strategy, but we prefer to use the paired random PAC and PRA (or PRC). Renin can be measured in terms of its enzymatic activity (PRA) or its mass (PRC) [<a href="#rid20">20</a>]. Details about PRA and PRC measurements are reviewed separately. (See  <a class="medical medical_review" href="/d/html/167.html" rel="external">"Assays of the renin-angiotensin-aldosterone system in adrenal disease", section on 'Renin'</a>.)</p><p>Blood samples should be collected in the morning (preferably 8 AM) from a seated, ambulatory patient  (<a class="graphic graphic_algorithm graphicRef111376" href="/d/graphic/111376.html" rel="external">algorithm 1</a>). Although some antihypertensive drugs may affect these laboratory measurements, most drugs may be continued during initial case-detection testing. Specific antihypertensive drugs are discussed in detail below. (See <a class="local">'Interfering drugs'</a> below.)</p><p class="headingAnchor" id="H870423692"><span class="h3">Test interpretation</span><span class="headingEndMark"> — </span>In patients with primary aldosteronism:</p><p class="bulletIndent1"><span class="glyph">●</span>The PRA and PRC are typically very low, due in part to the associated mild volume expansion. The PRA is usually &lt;1 ng/mL per hour (0.2778 ng/L per sec) and the PRC below the lower limit of normal  (<a class="graphic graphic_algorithm graphicRef111376" href="/d/graphic/111376.html" rel="external">algorithm 1</a>) [<a href="#rid21">21</a>]. Conversely, an increased PRA or PRC in a patient with hypokalemia and hypertension is most often due to diuretic therapy, renovascular or malignant hypertension, or, rarely, a renin-secreting tumor. (See <a class="local">'Other causes of hypertension and hypokalemia'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The PAC is usually &gt;10 ng/dL (277 pmol/L).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The PAC/PRA ratio is usually &gt;20 ng/dL per ng/mL/hour (&gt;555 pmol/L per ng/mL/hour)  (<a class="graphic graphic_table graphicRef87570" href="/d/graphic/87570.html" rel="external">table 1</a>). In one study, the combination of a PAC above 20 ng/dL (555 pmol/L) and a PAC/PRA ratio above 30 had a sensitivity and specificity of 90 percent for the diagnosis of APA [<a href="#rid21">21</a>]. </p><p></p><p>If findings on initial testing are negative despite high clinical suspicion for primary aldosteronism, we suggest repeat testing given the high degree of intra-individual variability in these analytes in individuals both with and without primary aldosteronism [<a href="#rid22">22,23</a>]. If case detection indicates underlying primary aldosteronism, most patients require subsequent, confirmatory testing. (See <a class="local">'Confirmation of the diagnosis'</a> below.)</p><p class="headingAnchor" id="H4292066932"><span class="h3">PAC to PRA ratio</span><span class="headingEndMark"> — </span>Some clinicians calculate a PAC/PRA ratio as part of the case-detection strategy, but this ratio is influenced by several laboratory- and assay-related variables. Therefore, we use the absolute PAC and PRA values to guide interpretation of this ratio rather than using the PAC/PRA ratio in isolation for case-detection testing  (<a class="graphic graphic_algorithm graphicRef111376" href="/d/graphic/111376.html" rel="external">algorithm 1</a>). The mean value for the PAC/PRA ratio in healthy individuals and patients with primary hypertension (formerly called "essential" hypertension) is 4 to 10, compared with &gt;30 to 50 in most patients with primary aldosteronism [<a href="#rid21">21,24</a>]. PRA and PRC are low in a significant number of patients with primary hypertension, but patients with a high PAC (typically &gt;10 ng/dL [277 pmol/L]) that is inappropriate for the corresponding PRA or PRC and a truly abnormal ratio are uncommon in the absence of primary aldosteronism.</p><p>In general, a PAC/PRA ratio &gt;20 (depending upon the laboratory reference range) is considered suspicious for primary aldosteronism, although others use a cutoff criterion of 30  (<a class="graphic graphic_table graphicRef87570" href="/d/graphic/87570.html" rel="external">table 1</a>) [<a href="#rid24">24</a>]. Cutoff values depend upon whether hormone concentrations are expressed in conventional or SI units, and they vary with the PRA assay. The lower limit of detection varies among the different PRA assays and can have a dramatic effect on the PAC/PRA ratio [<a href="#rid25">25</a>]. As an example, a very different ratio is obtained if the lower limit of detection for PRA is 0.6 ng/mL per hour compared with 0.1 ng/mL per hour; for a PAC of 16 ng/dL (444 pmol/L), the PAC/PRA ratio would be 27 and 160, respectively. For this reason, we favor a PAC &gt;10 ng/dL rather than the PAC/PRA for case detection  (<a class="graphic graphic_algorithm graphicRef111376" href="/d/graphic/111376.html" rel="external">algorithm 1</a>). Note that the conventional units for aldosterone are "ng/dL" and SI units are "pmol/L." To convert ng/dL to SI units, multiply by 27.74  (<a class="graphic graphic_table graphicRef87570" href="/d/graphic/87570.html" rel="external">table 1</a>).</p><p>The variability in threshold value for the PAC/PRA ratio is also illustrated by the range of thresholds used in various studies. In one study, in which blood was drawn at 8 AM after two hours of ambulation in 62 patients with primary aldosteronism (48 adrenal adenoma, 14 adrenal hyperplasia), 263 with presumed primary hypertension, and 434 patients with normotension, the combination of a PAC ≥20 ng/dL (555 pmol/L) and a PAC/PRA ratio &gt;30 had a sensitivity and specificity of 90 percent for the diagnosis of aldosterone-producing adenoma (APA) [<a href="#rid21">21</a>]. Other studies have suggested that better diagnostic discrimination might be achieved with a ratio ≥50 or ≥40 rather than &gt;30 [<a href="#rid24">24,26,27</a>], or with measurement of the ratio 60 to 90 minutes after a single dose of <a class="drug drug_general" data-topicid="9196" href="/d/drug information/9196.html" rel="external">captopril</a> [<a href="#rid28">28</a>] or <a class="drug drug_general" data-topicid="9574" href="/d/drug information/9574.html" rel="external">losartan</a> [<a href="#rid27">27</a>]. The latter tests are not widely used.</p><p class="headingAnchor" id="H2642912922"><span class="h3">Interfering drugs</span><span class="headingEndMark"> — </span>Most antihypertensive medications can be continued during biochemical testing,<strong> </strong>and posture stimulation is not required [<a href="#rid26">26,29-33</a>]. For example, although beta-adrenergic antagonists lower PRA and PRC concentrations and raise the PAC/PRA ratio [<a href="#rid33">33</a>], the increased PAC/PRA ratio is not clinically important in this setting because of the low PAC (&lt;10 ng/dL) in patients without primary aldosteronism [<a href="#rid33">33</a>]. In addition, the risks of modifying antihypertensive medication programs (eg, hypertensive crisis, severe hypokalemia, atrial fibrillation, heart failure) often argue against discontinuation of therapy [<a href="#rid34">34</a>].</p><p>Potentially clinically important issues exist with the following drugs:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mineralocorticoid receptor antagonists</strong> – Data obtained from patients treated with a mineralocorticoid receptor antagonist (<a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a><strong> and </strong><a class="drug drug_general" data-topicid="8789" href="/d/drug information/8789.html" rel="external">eplerenone</a>) may be difficult to interpret. These drugs prevent aldosterone from activating its receptor, resulting sequentially in sodium loss, a decrease in plasma volume, and an elevation in PRA, which could potentially lead to false-negative testing in a patient with primary aldosteronism. For this reason, spironolactone and eplerenone should not be initiated until the evaluation is completed and the final decisions about treatment are made.</p><p></p><p class="bulletIndent1">However, there are exceptions to this rule. For example, if the patient has hypokalemia despite treatment with <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a> or <a class="drug drug_general" data-topicid="8789" href="/d/drug information/8789.html" rel="external">eplerenone</a>, then the mineralocorticoid receptors are not fully blocked, and PRA or PRC should remain suppressed in patients with primary aldosteronism. Most patients with primary aldosteronism who are treated with mineralocorticoid receptor antagonists are given subtherapeutic doses. Thus, when there is clinical suspicion for primary aldosteronism in patients treated with spironolactone or eplerenone, PAC and PRA should be measured; if the PRA is suppressed in this setting, these medications are not interfering with the evaluation, and case-detection testing, confirmatory testing, and adrenal vein sampling (AVS) can be performed without discontinuing the mineralocorticoid receptor antagonists. However, if PRA is not suppressed, then the mineralocorticoid receptor antagonist should be discontinued for four to six weeks before retesting. Other potassium-sparing diuretics, such as <a class="drug drug_general" data-topicid="8550" href="/d/drug information/8550.html" rel="external">amiloride</a> and <a class="drug drug_general" data-topicid="10016" href="/d/drug information/10016.html" rel="external">triamterene</a>, usually do not interfere with testing unless the patient is on high doses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ACE inhibitors, ARBs, direct renin inhibitors</strong> – Angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and direct renin inhibitors could potentially elevate PRC and have variable effects on PRA in patients with primary aldosteronism. Thus, in a patient treated with one of these drugs, a PRA &gt;1 ng/mL/hour does <strong>not </strong>exclude the diagnosis of primary aldosteronism. On the other hand, a PRA &lt;1 ng/mL/hour or a PRC below the lower limit of normal in a patient taking one of these drugs is a strong predictor for primary aldosteronism.</p><p></p><p class="headingAnchor" id="H3697874181"><span class="h2">Other causes of hypertension and hypokalemia</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary hyperaldosteronism</strong> – Secondary hyperaldosteronism (eg, renovascular disease) should be considered when both the PRA (or PRC) and PAC are increased and the PAC/PRA ratio is &lt;10. In this setting, hypersecretion of renin leads sequentially to increased angiotensin II and then increased aldosterone secretion.</p><p></p><p class="bulletIndent1">An increased PRA or PRC in a patient with hypokalemia and hypertension is most often due to diuretic therapy, which may be surreptitious. Less common causes include renovascular or malignant hypertension and rare renin-secreting tumors  (<a class="graphic graphic_algorithm graphicRef111376" href="/d/graphic/111376.html" rel="external">algorithm 1</a>). Patients with renin-secreting tumors are typically young (average age 22 years in one report) and have severe hypertension and hypokalemia [<a href="#rid35">35</a>]. Contrast-enhanced CT appears to be the diagnostic procedure of choice since false-negative results occur with arteriography or renal vein renin sampling. Surgical removal of the tumor cures the disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liddle syndrome </strong>–<strong> </strong>Liddle syndrome is a rare autosomal dominant condition in which there is a primary increase in sodium reabsorption in the collecting tubules and, in most cases, potassium secretion. The underlying defect is a gain-of-function mutation in the collecting tubule sodium channel. The evaluation and management of Liddle syndrome are reviewed separately. (See  <a class="medical medical_review" href="/d/html/2371.html" rel="external">"Genetic disorders of the collecting tubule sodium channel: Liddle syndrome and pseudohypoaldosteronism type 1", section on 'Liddle syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cushing syndrome </strong>–<strong> </strong>Cushing syndrome can cause hypertension and hypokalemia due to the mineralocorticoid activity of cortisol. ACTH-mediated causes of Cushing syndrome further lead to hypersecretion of ACTH-dependent mineralocorticoids such as deoxycorticosterone and corticosterone. With ectopic ACTH syndrome, ACTH and cortisol hypersecretion are much higher than with an ACTH-secreting pituitary adenoma, leading to greater prevalence of hypokalemia (50 versus 9 percent in one series) [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/d/html/143.html" rel="external">"Epidemiology and clinical manifestations of Cushing syndrome"</a> and  <a class="medical medical_review" href="/d/html/156.html" rel="external">"Establishing the cause of Cushing syndrome"</a> and  <a class="medical medical_review" href="/d/html/2346.html" rel="external">"Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-aldosterone mineralocorticoid excess</strong> — The combination of suppressed PRA or PRC and a <strong>low</strong> plasma or urinary aldosterone value in a patient with hypertension and hypokalemia may indicate the presence of some non-aldosterone mineralocorticoid. In addition to Cushing syndrome, these findings can be evident in the following settings  (<a class="graphic graphic_algorithm graphicRef111376" href="/d/graphic/111376.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some types of congenital adrenal hyperplasia (deficiencies of 11-beta-hydroxylase [CYP11B1, P450c11] or 17-alpha-hydroxylase [CYP17, P450c17]) cause hypertension and hypokalemia because of hypersecretion of the mineralocorticoid deoxycorticosterone. Familial cortisol resistance has a similar presentation. (See  <a class="medical medical_review" href="/d/html/120.html" rel="external">"Adrenal steroid biosynthesis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A deoxycorticosterone-producing adrenal tumor, which can usually be detected by CT or magnetic resonance imaging (MRI), also leads to non-aldosterone mineralocorticoid excess [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other causes of mineralocorticoid excess include chronic licorice root ingestion and the rare genetic syndrome of apparent mineralocorticoid excess. (See  <a class="medical medical_review" href="/d/html/2346.html" rel="external">"Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)"</a>.)</p><p></p><p class="headingAnchor" id="H3732174509"><span class="h2">No role for urine potassium measurement</span><span class="headingEndMark"> — </span>We do not order a 24-hour urine potassium collection for the evaluation of primary hyperaldosteronism; the utility of this test is largely limited to clinical suspicion of surreptitious vomiting or laxative abuse. The low serum potassium concentration induced by mineralocorticoid excess is a result of increased urinary potassium excretion. Thus, in the past, a 24-hour urine collection was typically obtained to document the presence of inappropriate potassium wasting, defined as more than 30 mEq/day in a patient with hypokalemia. An appropriately low rate of potassium excretion may be evident in the setting of either extrarenal losses (vomiting, diarrhea) or active diuretic treatment with urine collected during a nadir of the diuretic effect.</p><p>Interpretation of the rate of potassium excretion requires attention to the patient's volume status and rate of sodium excretion. The patient must not have a low sodium intake or hypovolemia (as evidenced by less than 50 mEq of sodium being excreted per day), since the associated decrease in sodium and water delivery to the distal potassium secretory site can diminish potassium excretion even in patients with hyperaldosteronism. On the other hand, the degree of potassium wasting and, therefore, the diagnostic accuracy, can be increased by a high-sodium diet because the combination of increased distal flow and hypersecretion of aldosterone will maximize potassium losses [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H13"><span class="h1">CONFIRMATION OF THE DIAGNOSIS</span><span class="headingEndMark"> — </span>In patients with hypertension, an elevated plasma aldosterone concentration (PAC) ≥10 ng/dL (277 pmol/L) and low renin (plasma renin activity [PRA] &lt;1 ng/mL/hour or plasma renin concentration [PRC] less than the lower limit of normal) may reflect primary aldosteronism (high PAC, low PRA or PRC), secondary hyperaldosteronism (high PAC and nonsuppressed PRA or PRC), or non-aldosterone mineralocorticoid excess (low PAC, low PRA or PRC). The biochemical findings in these entities may overlap, and each can be caused by a variety of disorders. Therefore, subsequent confirmatory testing to demonstrate inappropriate aldosterone secretion is needed to verify primary aldosteronism in most patients  (<a class="graphic graphic_algorithm graphicRef111376" href="/d/graphic/111376.html" rel="external">algorithm 1</a>). The only exceptions to the requirement for confirmatory testing are the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with spontaneous hypokalemia, low PRA or PRC, and a PAC ≥20 ng/dL</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with low PRA or PRC and a PAC &gt;30 ng/dL</p><p></p><p>In a study of 252 patients with hypertension and suppressed renin, all 61 patients with PAC &gt;30 ng/dL were confirmed to have primary aldosteronism [<a href="#rid38">38</a>]. In addition, all 26 patients with spontaneous hypokalemia and PAC between 20 to 30 ng/dL were confirmed to have primary aldosteronism [<a href="#rid38">38</a>].</p><p>However, aldosterone suppression testing is usually needed, and it can be performed with orally administered sodium chloride and measurement of urine aldosterone excretion or with intravenous sodium chloride loading and measurement of PAC [<a href="#rid31">31,39</a>].</p><p class="headingAnchor" id="H15"><span class="h2">Oral sodium loading</span><span class="headingEndMark"> — </span>Many centers and experts, including the author of this topic, use oral sodium loading over three days. After hypertension and hypokalemia are controlled (hypokalemia suppresses aldosterone secretion), the patient should receive a high-sodium diet for three days.</p><p class="headingAnchor" id="H328108572"><span class="h3">Testing protocol</span><span class="headingEndMark"> — </span>Patients should be given guidance on the sodium content of the types of food they need to consume to achieve a 5000 mg sodium diet. Alternatively, particularly if patients have a taste aversion to high-sodium foods, they can be given oral sodium chloride tablets (eg, two 1 g sodium chloride tablets taken three times daily with food will provide approximately 90 mEq of sodium). On the third day of the high-sodium diet, serum electrolytes are measured, and a 24-hour urine specimen is collected for measurement of aldosterone, sodium, and creatinine. The 24-hour urine sodium excretion should exceed 200 mEq (4600 mg) to document adequate sodium loading. Urine aldosterone excretion &gt;12 mcg/24 hours (33 nmol/day) in this setting is consistent with hyperaldosteronism. (See  <a class="medical medical_patient" href="/d/html/2181.html" rel="external">"Patient education: Collection of a 24-hour urine specimen (Beyond the Basics)"</a>.)</p><p>During oral sodium loading, the serum potassium level should be measured daily. Sodium-induced hypokalemia itself is strongly suggestive of nonsuppressible hyperaldosteronism. Healthy individuals do not waste potassium during sodium loading, because the increase in distal flow is offset by reduced secretion of aldosterone.</p><p class="headingAnchor" id="H2919973610"><span class="h3">Risks and safety precautions</span><span class="headingEndMark"> — </span>The risk of increasing dietary sodium in patients with severe hypertension must be assessed for each individual. In addition, since sodium loading typically increases kaliuresis and hypokalemia, patients are at risk for severe hypokalemia. Vigorous replacement of <a class="drug drug_general" data-topicid="9795" href="/d/drug information/9795.html" rel="external">potassium chloride</a> should be prescribed as indicated.</p><p class="headingAnchor" id="H16"><span class="h2">Saline infusion test</span><span class="headingEndMark"> — </span>An alternate method to suppress endogenous aldosterone production is by the intravenous administration of 2 L of isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> over four hours (from 8 AM to 12 PM), ideally while the patient is seated [<a href="#rid39">39,40</a>]. The PAC will fall below 5 ng/dL (139 pmol/L) in healthy individuals, whereas values above 10 ng/dL (277 pmol/L) are consistent with primary aldosteronism [<a href="#rid39">39</a>]. False-negative rates may be as high as 30 percent, but they appear to be lower if the test is performed with the patient seated rather than recumbent [<a href="#rid40">40,41</a>].</p><p class="headingAnchor" id="H166293160"><span class="h2">Other</span><span class="headingEndMark"> — </span>Other available confirmation tests include the <a class="drug drug_general" data-topicid="8455" href="/d/drug information/8455.html" rel="external">fludrocortisone</a> suppression and <a class="drug drug_general" data-topicid="9196" href="/d/drug information/9196.html" rel="external">captopril</a> challenge tests. As noted above, we prefer oral sodium loading. (See <a class="local">'Oral sodium loading'</a> above.)</p><p class="headingAnchor" id="H17"><span class="h1">SUBTYPE CLASSIFICATION</span><span class="headingEndMark"> — </span>Once the diagnosis of primary aldosteronism has been established, a unilateral aldosterone-producing adenoma (APA), or rarely, carcinoma, must be distinguished from bilateral hyperplasia (idiopathic hyperaldosteronism [IHA]). This distinction is important since the treatment options differ for these disorders. We suggest the algorithm developed at the Mayo Clinic that uses adrenal CT and adrenal vein sampling (AVS) to differentiate between these etiologies  (<a class="graphic graphic_algorithm graphicRef76673" data-inline-graphics="76673" href="/d/graphic/76673.html" rel="external">algorithm 2</a>) [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/141.html" rel="external">"Treatment of primary aldosteronism"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>APA</strong> – In general, patients with APA have higher aldosterone secretion rates, resulting in more severe hypertension, more profound hypokalemia (&lt;3.2 mEq/L), and higher plasma (&gt;25 ng/dL) and urinary (&gt;30 mcg/24 hour) levels of aldosterone; these patients are also typically younger (age &lt;50 years) than those with IHA [<a href="#rid31">31</a>]. In one study, a plasma aldosterone concentration (PAC)/plasma renin activity (PRA) ratio of &gt;32 had a sensitivity of 100 percent and specificity of 61 percent for an APA [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1">The genetic basis of APA can be established in a substantial number of patients. Somatic mutations in <em>KCNJ5</em>, <em>ATP1A1</em>, <em>ATP2B3</em>, <em>CTNNB1</em>, and <em>CACNA1D</em> are found in more than 80 percent of resected APAs [<a href="#rid42">42-45</a>]. In a study of 474 unselected patients with APAs, somatic heterozygous <em>KCNJ5</em> mutations were present in 38 percent of patients, <em>CACNA1D</em> mutations in 9.3 percent, <em>ATP1A1</em> mutations in 5.3 percent, and <em>ATP2B3</em> mutations in 1.7 percent. Patients with <em>KCNJ5</em> mutations were more frequently female and diagnosed at a younger age compared with <em>CACNA1D</em> mutation carriers or noncarriers [<a href="#rid43">43</a>]. Nonetheless, the presence of one of these somatic mutations does not affect diagnosis or treatment. (See  <a class="medical medical_review" href="/d/html/140.html" rel="external">"Pathophysiology and clinical features of primary aldosteronism", section on 'Mutations in aldosterone-producing adenomas'</a> and <a class="local">'Familial hyperaldosteronism'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IHA</strong> – Bilateral adrenal hyperplasia, which accounts for approximately 60 percent of cases, is generally a milder disease with less hypersecretion of aldosterone and less frequent hypokalemia; it should be treated with a mineralocorticoid receptor antagonist. The genetic basis of primary aldosteronism due to bilateral adrenal hyperplasia has not yet been determined. (See  <a class="medical medical_review" href="/d/html/141.html" rel="external">"Treatment of primary aldosteronism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Co-existing APA and IHA</strong> – The clear distinction between unilateral aldosteronoma and bilateral adrenal hyperplasia has been challenged by the demonstration of the frequent presence of zona glomerulosa hyperplasia and aldosterone-producing micronodules adjacent to the dominant aldosteronoma. In addition, while ion channel mutations are frequently found in the dominant aldosteronoma, they are not present in the adjacent hyperplasia, suggesting that somatic development of a dominant adenoma may occur in a background of bilateral mild hyperplasia [<a href="#rid46">46,47</a>].</p><p></p><p class="headingAnchor" id="H18"><span class="h2">Adrenal CT</span><span class="headingEndMark"> — </span>Adrenal computed tomography (CT) should be the initial study to determine subtype (adenoma versus hyperplasia) and exclude adrenal carcinoma [<a href="#rid48">48</a>]. For adrenal gland imaging, CT has superior spatial resolution compared with MRI. The CT scan may be done without intravenous contrast; however, if an adrenal mass is detected, contrast administration provides additional imaging information. (See  <a class="medical medical_review" href="/d/html/153.html" rel="external">"Evaluation and management of the adrenal incidentaloma", section on 'Typical imaging features'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>An adrenal carcinoma should be suspected when a unilateral, large (&gt;4 cm) adrenal mass is found on CT in a patient with primary aldosteronism  (<a class="graphic graphic_diagnosticimage graphicRef79992" href="/d/graphic/79992.html" rel="external">image 1</a>) [<a href="#rid49">49-53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bilateral adrenal gland thickening or micronodular changes suggests adrenal hyperplasia; however, patients with hyperplasia may also have normal-appearing adrenal glands on CT [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When a solitary, hypodense, unilateral macroadenoma (&gt;1 cm) and normal contralateral adrenal morphology  (<a class="graphic graphic_diagnosticimage graphicRef50033" data-inline-graphics="50033" href="/d/graphic/50033.html" rel="external">image 2</a>) are found in a young patient (&lt;35 years of age) with unequivocal primary aldosteronism (defined as spontaneous hypokalemia and PAC &gt;30 ng/dL), unilateral adrenalectomy is a reasonable therapeutic option [<a href="#rid54">54</a>]. However, because of the age-dependent risk that a solitary unilateral adrenal macroadenoma may be a nonfunctioning cortical adenoma, AVS should be considered in patients over 35 years of age who want to pursue a surgical cure of hyperaldosteronism  (<a class="graphic graphic_algorithm graphicRef76673" href="/d/graphic/76673.html" rel="external">algorithm 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For macroadenomas ≥1.5 cm that likely represent an APA, assessment for cortisol cosecretion is warranted, as this informs subsequent management decisions. (See <a class="local">'Cortisol cosecretion'</a> below.)</p><p></p><p class="headingAnchor" id="H19"><span class="h3">Limitations</span><span class="headingEndMark"> — </span>Some investigators suggest that the findings of hypokalemia, nonsuppressible hyperaldosteronism, a PAC/PRA ratio exceeding 50, and a unilateral mass on CT can be followed directly by surgery to remove a presumed adenoma [<a href="#rid24">24</a>]. However, CT findings are frequently misleading, as many patients with biochemical evidence of nonsuppressible hyperaldosteronism and a unilateral adrenal mass turn out to have bilateral hyperplasia [<a href="#rid51">51,53,55-57</a>].</p><p>Another problem is that the absence of a mass does not exclude an adenoma since APAs can be very small (eg, &lt;3 mm in diameter), and lesions &lt;1 cm in diameter may be missed on CT. Further, bilateral lesions are not diagnostic of hyperplasia because some patients with an aldosteronoma in one adrenal gland have a nonfunctioning adrenal nodule in the other [<a href="#rid52">52,53</a>].</p><p>The limitations of adrenal CT were illustrated in a study of 203 patients with primary aldosteronism who were evaluated with both CT and AVS; CT was accurate in only 53 percent of patients [<a href="#rid56">56</a>]. Based upon CT, 42 patients (22 percent) would have been incorrectly excluded as candidates for adrenalectomy, and 48 (25 percent) might have had unnecessary or inappropriate surgery. In another study, CT findings coincided with the lateralization determined by AVS in only 80 of 158 (51 percent) patients [<a href="#rid58">58</a>].</p><p>In a subsequent systematic review of 38 studies in a total of 950 patients with primary aldosteronism (including the 203 patients described above), adrenal CT/MRI results did not agree with AVS in 359 of 950 patients (37.8 percent) [<a href="#rid57">57</a>]. If CT/MRI alone had been used to determine subtype, the following inappropriate treatment would have been recommended:</p><p class="bulletIndent1"><span class="glyph">●</span>139 patients (14.6 percent) would have inappropriately undergone unilateral adrenalectomy (unilateral mass on CT/MRI but bilateral findings on AVS), which would not have been curative.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>181 patients (19.1 percent) would have been offered medical therapy instead of curative adrenalectomy (bilateral findings on CT/MRI but unilateral secretion on AVS).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>37 patients (3.9 percent) would have undergone adrenalectomy on the wrong side (AVS showing unilateral secretion on the opposite side of CT/MRI abnormalities).</p><p></p><p>These observations highlight the importance of performing AVS in most patients to distinguish between unilateral and bilateral adrenal aldosterone hypersecretion. (See <a class="local">'Adrenal vein sampling'</a> below.)</p><p>The role of CT and MRI in the evaluation of incidental adrenal masses is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/153.html" rel="external">"Evaluation and management of the adrenal incidentaloma", section on 'MRI'</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Adrenal vein sampling</span><span class="headingEndMark"> — </span>Measurement of aldosterone in samples of adrenal venous blood, obtained by an experienced interventional radiologist, is the criterion standard test to distinguish between unilateral adenoma and bilateral hyperplasia [<a href="#rid59">59</a>]. Unilateral disease is associated with a marked (usually fourfold greater than contralateral adrenal) increase in PAC on the side of the tumor, whereas there is little difference between the two sides in patients with bilateral hyperplasia  (<a class="graphic graphic_figure graphicRef71391" href="/d/graphic/71391.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef109110" href="/d/graphic/109110.html" rel="external">figure 2</a>) [<a href="#rid56">56,60,61</a>].</p><p>Performance of AVS by experienced personnel is critical to optimize test success and minimize complications. One limitation of AVS is an inability to obtain good samples as the right adrenal vein is small and sometimes difficult to locate; due to this and other technical challenges, success rates vary in part with local expertise. In two series, catheterization was successful in 43 of 49 patients (88 percent) and 194 of 203 patients (96 percent), respectively  (<a class="graphic graphic_figure graphicRef109110" href="/d/graphic/109110.html" rel="external">figure 2</a>) [<a href="#rid55">55,56</a>]. The complication rate in published studies of AVS is 2.5 percent or less [<a href="#rid56">56,62-65</a>]. The most common complication is groin hematoma; adrenal hemorrhage and adrenal vein dissection are rare [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H21"><span class="h3">Indications</span><span class="headingEndMark"> — </span>For patients who would like to pursue surgical management (unilateral adrenalectomy) of their primary aldosteronism, we suggest AVS to confirm unilateral disease if the CT scan is normal, shows bilateral abnormalities, or shows a unilateral abnormality in a patient over age 35 years [<a href="#rid54">54</a>].</p><p>We suggest that AVS may not be needed in patients under age 35 years who have severe primary aldosteronism (spontaneous hypokalemia and PAC &gt;30 ng/dL) and who have a unilateral adrenal macroadenoma (&gt;1 cm and &lt;2 cm), because they are unlikely to have a nonfunctioning adrenal adenoma that could be confused with an APA  (<a class="graphic graphic_algorithm graphicRef76673" href="/d/graphic/76673.html" rel="external">algorithm 2</a>). The development of adrenocortical nodularity is, in part, a function of age.</p><p>Other factors to consider before recommending AVS include the presence of comorbid conditions that could increase surgical risk and the probability of finding an APA [<a href="#rid67">67</a>]. APA is more likely in patients who have spontaneous hypokalemia and marked elevations in aldosterone in blood (eg, &gt;30 ng/dL) or 24-hour urine collection (eg, &gt;30 mcg).</p><p class="headingAnchor" id="H22"><span class="h3">Procedure</span><span class="headingEndMark"> — </span>Some centers perform AVS without cosyntropin stimulation, but we prefer <strong>continuous cosyntropin infusion</strong> (50 mcg per hour started 30 minutes before sequential sampling of the adrenal veins and continued throughout the procedure) for the following reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>To minimize stress-induced fluctuations in aldosterone secretion during nonsimultaneous AVS, which could potentially confound the interpretation of lateralization data.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To maximize the gradient in cortisol from adrenal vein to inferior vena cava (IVC) and thus confirm successful sampling of the adrenal vein.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To maximize the secretion of aldosterone from an APA [<a href="#rid56">56,60</a>].</p><p></p><p>Some investigators have suggested that when given as a bolus injection and when the adrenal veins are sampled simultaneously, cosyntropin administration does not improve the diagnostic accuracy of AVS and may misclassify some patients [<a href="#rid61">61,62,68,69</a>]. However, as noted above, we suggest <strong>continuous cosyntropin infusion </strong>for optimal results [<a href="#rid56">56,60</a>]. Confidence in successful cannulation of both adrenal veins is critical to patient care. If the clinician cannot be confident that both adrenal veins were successfully sampled, the AVS data are not clinically useful.</p><p>Aldosterone and cortisol concentrations are measured in the blood from all three sites (right adrenal vein, left adrenal vein, and IVC). All of the blood samples should be assayed at 1:1, 1:10, and 1:50 dilutions; absolute values and accurate laboratory assays for cortisol and aldosterone are essential for successful interpretation of the AVS data. An AVS-specific report should be developed by the laboratory to prevent any confusion on data interpretation  (<a class="graphic graphic_figure graphicRef109110" href="/d/graphic/109110.html" rel="external">figure 2</a>) [<a href="#rid31">31,56,63</a>].</p><p class="headingAnchor" id="H23"><span class="h3">Confirming successful catheterization</span><span class="headingEndMark"> — </span>The cortisol concentrations from the adrenal veins and IVC are used to confirm successful cannulation of both adrenal veins. With cosyntropin infusion, the adrenal vein to IVC cortisol ratio is typically more than 10:1 [<a href="#rid56">56</a>]; a ratio of at least 5:1 is required to be confident that the adrenal veins were successfully catheterized  (<a class="graphic graphic_figure graphicRef109110" href="/d/graphic/109110.html" rel="external">figure 2</a>).</p><p>However, when cosyntropin infusion is not used, an adrenal vein to IVC cortisol gradient of more than 3:1 is recommended as the threshold to verify successful catheterization [<a href="#rid64">64</a>]. Some centers require only a 10 percent gradient between an adrenal vein and the IVC [<a href="#rid61">61,62</a>], a change that can be seen in minute-to-minute adrenal cortisol secretion and that is within the coefficient of variation of some cortisol assays. Thus, as noted, we suggest cosyntropin infusion during AVS.</p><p class="headingAnchor" id="H24"><span class="h3">Cortisol-corrected ratios</span><span class="headingEndMark"> — </span>Dividing the right and left adrenal vein PAC by their respective cortisol concentrations corrects for the dilutional effect of the inferior phrenic vein flow into the left adrenal vein; these are termed "cortisol-corrected ratios."</p><p class="bulletIndent1"><span class="glyph">●</span>At Mayo Clinic, where AVS is performed with cosyntropin infusion, the mean cortisol-corrected aldosterone ratio (APA-side PAC/cortisol to normal adrenal PAC/cortisol) in patients with confirmed APA is 18:1 [<a href="#rid56">56</a>]. We use a cutoff for the cortisol-corrected aldosterone ratio from high-side to low-side of more than 4:1 to indicate unilateral aldosterone excess [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with presumed IHA, the mean cortisol-corrected aldosterone ratio is 1.8:1 (high-side to low-side); a ratio less than 3:1 is suggestive of bilateral aldosterone hypersecretion [<a href="#rid56">56</a>].</p><p></p><p>Thus, most patients with a unilateral source of aldosterone will have cortisol-corrected aldosterone lateralization ratios greater than 4; ratios greater than 3, but less than 4, represent a zone of overlap. A ratio less than 3 is consistent with bilateral aldosterone hypersecretion [<a href="#rid56">56</a>].</p><p>In addition, the contralateral aldosterone to cortisol ratio is less than the IVC aldosterone to cortisol ratio in 93 percent of patients with surgically confirmed APA [<a href="#rid56">56</a>], indicative of suppression of aldosterone secretion by the noninvolved adrenal gland.</p><p>Centers that perform AVS without cosyntropin infusion use lower lateralization cutoff values [<a href="#rid61">61,62</a>]. However, using the diagnostic cutoffs described above for cosyntropin-stimulated AVS, the sensitivity and specificity for detecting unilateral aldosterone hypersecretion are 95 and 98.6 percent, respectively [<a href="#rid54">54</a>]. These test characteristics deteriorate when lower cutoffs are used to determine successful catheterization and lateralization.</p><p class="headingAnchor" id="H25"><span class="h3">Special circumstances</span><span class="headingEndMark"> — </span>AVS may be most useful when no adrenal abnormality is found on CT or when both adrenal glands are abnormal but asymmetric. In one report, for example, 24 of 58 patients (41 percent) with normal adrenal CT and 16 of 33 (49 percent) with bilateral micronodules on CT had a unilateral source of aldosterone by AVS [<a href="#rid56">56</a>].</p><p>There are isolated cases of primary aldosteronism due to an ectopic adrenal adenoma (as in the kidney) [<a href="#rid70">70</a>]. These patients have low serum aldosterone concentrations in AVS, and CT or MRI may identify the site of the tumor.</p><p class="headingAnchor" id="H26"><span class="h2">Tests not recommended</span><span class="headingEndMark"> — </span>Other tests that predate the current approach with adrenal CT and AVS were used to distinguish unilateral APAs from bilateral disease but have limited clinical utility. These tests include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Posture stimulation test</strong> – The posture stimulation test was based upon the observation that patients with bilateral idiopathic hyperplasia have a characteristic rise in PAC when going from the supine to standing position; this phenomenon has been ascribed to an enhanced sensitivity of the adrenal zona glomerulosa to the small changes in angiotensin II that occur with standing [<a href="#rid71">71</a>]. In contrast, no such changes would be expected in patients with an APA because their aldosterone hypersecretion is autonomous and diurnal.</p><p></p><p class="bulletIndent1">However, this test does not discriminate well between unilateral adenoma and bilateral hyperplasia [<a href="#rid7">7,49,72,73</a>]. As an example, in a study of 20 patients with primary aldosteronism (15 with a unilateral APA) undergoing a postural stimulation test, PAC increased after four hours of standing in all patients with hyperplasia and in 8 of 15 patients with adenomas (based upon a 30 percent rise) [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>18-hydroxycorticosterone</strong> – Patients with an APA typically have elevated supine plasma 18-hydroxycorticosterone levels at 8 AM (&gt;100 ng/dL), whereas patients with bilateral IHA do not [<a href="#rid48">48</a>]. However, the accuracy of the test is low, and it does not help with localization [<a href="#rid48">48,73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iodocholesterol scintigraphy</strong> – Radionuclide scintigraphy with 131-I-iodocholesterol or an analog (NP-59) is no longer used in most centers. While it has the potential advantage of correlating function with anatomic findings, it is not useful for evaluating small adrenal nodules, as tracer uptake is poor in APAs &lt;1.5 cm in diameter [<a href="#rid74">74</a>]. This imaging modality is no longer available in the United States.</p><p></p><p class="headingAnchor" id="H27"><span class="h2">Familial hyperaldosteronism</span><span class="headingEndMark"> — </span>There are four rare forms of familial hyperaldosteronism (FH) associated with adrenal hyperplasia (see  <a class="medical medical_review" href="/d/html/122.html" rel="external">"Familial hyperaldosteronism"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>FH type I or glucocorticoid-remediable aldosteronism (GRA) due to a <em>CYP11B1/CYP11B2</em> chimeric gene</p><p class="bulletIndent1"><span class="glyph">●</span>FH type II, caused by germline pathogenic variants in the chloride channel <em>CLCN2</em> [<a href="#rid75">75</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>FH type III, caused by germline pathogenic variants in the potassium channel subunit <em>KCNJ5</em></p><p class="bulletIndent1"><span class="glyph">●</span>FH type IV, caused by germline pathogenic variants in the <em>CACNA1H</em> gene, which encodes the alpha subunit of an L-type voltage-gated calcium channel (Cav3.2)</p><p></p><p class="headingAnchor" id="H445208040"><span class="h1">CORTISOL COSECRETION</span><span class="headingEndMark"> — </span>Clinically important aldosterone-producing adenoma (APA) cosecretion of cortisol may occur in patients with larger APAs (eg, ≥1.5 cm in diameter) [<a href="#rid76">76</a>]. It is reasonable to screen for this possibility in patients with apparent APAs ≥1.5 cm in diameter by measuring a baseline serum dehydroepiandrosterone sulfate (DHEAS) and performing a 1 mg overnight <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> suppression test.</p><p>If autonomous cortisol cosecretion is present in a patient with primary aldosteronism and a unilateral adrenal macroadenoma, then adrenal vein sampling (AVS) is not needed. In this setting, the macroadenoma is usually cosecreting aldosterone and cortisol. However, even if the patient has primary aldosteronism caused by bilateral idiopathic hyperplasia or a contralateral adrenal micronodule, adrenalectomy remains warranted for management of hypercortisolism because good, long-term medical treatment options are not available for hypercortisolism. In contrast, if primary aldosteronism persists following unilateral adrenalectomy, mineralocorticoid receptor antagonists are an excellent treatment. When autonomous cortisol cosecretion is documented, patients must be treated perioperatively with stress doses of glucocorticoids followed by a planned postoperative taper. (See  <a class="medical medical_review" href="/d/html/174.html" rel="external">"Overview of the treatment of Cushing syndrome", section on 'Adrenal adenomas'</a>.)</p><p class="headingAnchor" id="H496847591"><span class="h1">PREGNANCY</span><span class="headingEndMark"> — </span>Primary aldosteronism is uncommon in pregnancy, with fewer than 60 patients reported in the medical literature; most of these patients have had aldosterone-producing adenomas (APAs) [<a href="#rid77">77-81</a>]. Primary aldosteronism can lead to intrauterine growth retardation, preterm delivery, intrauterine fetal demise, and placental abruption [<a href="#rid81">81,82</a>].</p><p>Case-detection testing for primary aldosteronism during pregnancy is the same as for nonpregnant patients: morning blood sample for the measurement of plasma aldosterone concentration (PAC) and plasma renin activity (PRA) or renin concentration (PRC) (see <a class="local">'Patient selection'</a> above). Suppressed renin and an aldosterone level &gt;10 ng/dL is a positive case-detection test for primary aldosteronism. If spontaneous hypokalemia is present with high aldosterone (≥20 ng/dL) and suppressed renin, confirmatory testing is not needed. In patients with normokalemia and a positive case-detection test, confirmatory testing should be pursued. However, the <a class="drug drug_general" data-topicid="9196" href="/d/drug information/9196.html" rel="external">captopril</a> stimulation test is contraindicated in pregnancy, and the <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> infusion test may not be well tolerated. One option is measurement of sodium and aldosterone in a 24-hour urine collection on an ambient sodium diet. (See <a class="local">'Confirmation of the diagnosis'</a> above.)</p><p>Subtype testing with abdominal MRI without gadolinium is the test of choice. Adrenal imaging with CT, iodocholesterol scintigraphy, and adrenal vein sampling (AVS) should be <strong>avoided</strong> in pregnancy. As highlighted in the revised Endocrine Society guidelines on primary aldosteronism [<a href="#rid5">5</a>], AVS may not be needed in patients with severe primary aldosteronism (ie, spontaneous hypokalemia and PAC &gt;30 ng/dL) who are less than 35 years old and have a clear-cut, unilateral adrenal adenoma on cross-sectional imaging [<a href="#rid54">54</a>]. (See <a class="local">'Subtype classification'</a> above and  <a class="medical medical_review" href="/d/html/141.html" rel="external">"Treatment of primary aldosteronism", section on 'Pregnancy'</a>.)</p><p class="headingAnchor" id="H2967079431"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114450.html" rel="external">"Society guideline links: Primary aldosteronism"</a>.)</p><p class="headingAnchor" id="H28"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes of primary aldosteronism</strong> – The most common causes of primary aldosteronism are aldosterone-producing adenomas (APAs) and bilateral idiopathic hyperaldosteronism (IHA). Other, rarer causes include familial hyperaldosteronism (FH) type I (glucocorticoid-remediable aldosteronism [GRA]), type II, type III, or type IV. (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/d/html/122.html" rel="external">"Familial hyperaldosteronism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence and presentation</strong> – The prevalence of nonsuppressible (primary) hypersecretion of aldosterone is considerably higher than previously thought. The classic presenting signs of primary aldosteronism are hypertension and hypokalemia. However, normokalemia is more common than hypokalemia in patients diagnosed with primary aldosteronism. (See <a class="local">'Prevalence of primary aldosteronism'</a> above and <a class="local">'Variable presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Identifying primary aldosteronism is important because of its high prevalence and association with increased cardiovascular morbidity and mortality relative to primary hypertension with the same degree of blood pressure elevation. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Case detection</strong> – Consistent with the Endocrine Society guidelines, we recommend case-detection testing for primary aldosteronism in patients with any of the following  (<a class="graphic graphic_algorithm graphicRef111376" href="/d/graphic/111376.html" rel="external">algorithm 1</a>) (see <a class="local">'Patient selection'</a> above and <a class="local">'Case detection'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hypertension and spontaneous or diuretic-induced hypokalemia</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Severe hypertension (&gt;150 mmHg systolic or &gt;100 mmHg diastolic) or drug-resistant hypertension (defined as suboptimally controlled hypertension on a three-drug program that includes an adrenergic inhibitor, vasodilator, and diuretic)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hypertension with an adrenal incidentaloma</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hypertension with sleep apnea</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hypertension and a family history of early-onset hypertension or cerebrovascular accident at a young age (&lt;40 years)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hypertension and a first-degree relative with primary aldosteronism</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hypertension and atrial fibrillation</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial testing</strong> – The initial evaluation should consist of documenting that the plasma renin activity (PRA) or plasma renin concentration (PRC) is reduced (PRA &lt;1 ng/mL/hour, PRC less than the lower limit of the reference range) and that the plasma aldosterone concentration (PAC) is inappropriately high for the PRA (typically &gt;10 ng/dL [&gt;277 pmol/L]); the net effect is a PAC/PRA ratio greater than 20 (depending upon the laboratory normals). As noted above, we prefer to use the paired random PAC and PRA (or PRC) for case detection rather than the PAC/PRA ratio  (<a class="graphic graphic_table graphicRef87570" href="/d/graphic/87570.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef111376" href="/d/graphic/111376.html" rel="external">algorithm 1</a>). (See <a class="local">'Diagnosis'</a> above and <a class="local">'Case detection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Confirmation of the diagnosis</strong> – We recommend confirming the diagnosis by demonstrating inappropriate aldosterone secretion. For aldosterone suppression testing, we use oral sodium loading and measurement of urine aldosterone excretion. Some experts prefer intravenous sodium chloride loading and measurement of the PAC.</p><p></p><p class="bulletIndent2">The exceptions to the requirement for confirmatory testing are the patients with spontaneous hypokalemia, low PRA or PRC, and a PAC ≥20 ng/dL, or those patients without spontaneous hypokalemia but with low PRA or PRC and a PAC &gt;30 ng/dL; in these clinical settings, only primary aldosteronism can explain the findings. (See <a class="local">'Confirmation of the diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subtype classification</strong> – We suggest adrenal CT as the initial test to distinguish between APA and bilateral hyperplasia. Adrenal CT will also exclude adrenocortical carcinoma  (<a class="graphic graphic_algorithm graphicRef76673" href="/d/graphic/76673.html" rel="external">algorithm 2</a>). (See <a class="local">'Adrenal CT'</a> above.)</p><p></p><p class="bulletIndent1">In patients over the age of 35 years, when the CT scan is normal, shows bilateral abnormalities, or shows a unilateral abnormality, we recommend adrenal vein sampling (AVS) to confirm unilateral disease if the patient would like to pursue surgical management of their primary aldosteronism  (<a class="graphic graphic_figure graphicRef109110" href="/d/graphic/109110.html" rel="external">figure 2</a> and <a class="graphic graphic_algorithm graphicRef76673" href="/d/graphic/76673.html" rel="external">algorithm 2</a>). AVS may not be needed in patients under age 35 years who have severe primary aldosteronism (spontaneous hypokalemia and PAC &gt;30 ng/dL) and who have a unilateral adrenal macroadenoma (&gt;1 cm and &lt;2 cm). (See <a class="local">'Adrenal vein sampling'</a> above.)</p><p></p><p class="bulletIndent1">AVS should only be performed by an experienced radiologist. (See <a class="local">'Adrenal vein sampling'</a> above.)</p><p></p><p class="headingAnchor" id="H1289157252"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.</p><p>The UpToDate editorial staff acknowledges Norman M Kaplan, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89:1045.</a></li><li><a class="nounderline abstract_t">Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371:1921.</a></li><li><a class="nounderline abstract_t">Käyser SC, Dekkers T, Groenewoud HJ, et al. Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. J Clin Endocrinol Metab 2016; 101:2826.</a></li><li><a class="nounderline abstract_t">Monticone S, Burrello J, Tizzani D, et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol 2017; 69:1811.</a></li><li><a class="nounderline abstract_t">Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101:1889.</a></li><li><a class="nounderline abstract_t">Brown JM, Siddiqui M, Calhoun DA, et al. The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study. Ann Intern Med 2020; 173:10.</a></li><li><a class="nounderline abstract_t">Gordon RD. Mineralocorticoid hypertension. Lancet 1994; 344:240.</a></li><li><a class="nounderline abstract_t">Stewart PM. Mineralocorticoid hypertension. Lancet 1999; 353:1341.</a></li><li><a class="nounderline abstract_t">Mattsson C, Young WF Jr. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol 2006; 2:198.</a></li><li><a class="nounderline abstract_t">Kono T, Ikeda F, Oseko F, et al. Normotensive primary aldosteronism: report of a case. J Clin Endocrinol Metab 1981; 52:1009.</a></li><li><a class="nounderline abstract_t">Monticone S, D'Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018; 6:41.</a></li><li><a class="nounderline abstract_t">Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48:2293.</a></li><li><a class="nounderline abstract_t">Loh KC, Koay ES, Khaw MC, et al. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85:2854.</a></li><li><a class="nounderline abstract_t">Hundemer GL, Curhan GC, Yozamp N, et al. Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism. JAMA Cardiol 2018; 3:768.</a></li><li><a class="nounderline abstract_t">Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med 2019; 285:126.</a></li><li><a class="nounderline abstract_t">Cohen JB, Cohen DL, Herman DS, et al. Testing for Primary Aldosteronism and Mineralocorticoid Receptor Antagonist Use Among U.S. Veterans : A Retrospective Cohort Study. Ann Intern Med 2021; 174:289.</a></li><li><a class="nounderline abstract_t">Jaffe G, Gray Z, Krishnan G, et al. Screening Rates for Primary Aldosteronism in Resistant Hypertension: A Cohort Study. Hypertension 2020; 75:650.</a></li><li><a class="nounderline abstract_t">Ruhle BC, White MG, Alsafran S, et al. Keeping primary aldosteronism in mind: Deficiencies in screening at-risk hypertensives. Surgery 2019; 165:221.</a></li><li><a class="nounderline abstract_t">Hundemer GL, Imsirovic H, Vaidya A, et al. Screening Rates for Primary Aldosteronism Among Individuals With Hypertension Plus Hypokalemia: A Population-Based Retrospective Cohort Study. Hypertension 2022; 79:178.</a></li><li><a class="nounderline abstract_t">Manolopoulou J, Fischer E, Dietz A, et al. Clinical validation for the aldosterone-to-renin ratio and aldosterone suppression testing using simultaneous fully automated chemiluminescence immunoassays. J Hypertens 2015; 33:2500.</a></li><li><a class="nounderline abstract_t">Weinberger MH, Fineberg NS. The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med 1993; 153:2125.</a></li><li><a class="nounderline abstract_t">Ng E, Gwini SM, Libianto R, et al. Aldosterone, Renin, and Aldosterone-to-Renin Ratio Variability in Screening for Primary Aldosteronism. J Clin Endocrinol Metab 2022; 108:33.</a></li><li><a class="nounderline abstract_t">Maciel AAW, Freitas TC, Fagundes GFC, et al. Intra-individual Variability of Serum Aldosterone and Implications for Primary Aldosteronism Screening. J Clin Endocrinol Metab 2023; 108:1143.</a></li><li><a class="nounderline abstract_t">Blumenfeld JD, Sealey JE, Schlussel Y, et al. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994; 121:877.</a></li><li><a class="nounderline abstract_t">Montori VM, Schwartz GL, Chapman AB, et al. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc 2001; 76:877.</a></li><li><a class="nounderline abstract_t">Hirohara D, Nomura K, Okamoto T, et al. Performance of the basal aldosterone to renin ratio and of the renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low renin hypertensives. J Clin Endocrinol Metab 2001; 86:4292.</a></li><li><a class="nounderline abstract_t">Giacchetti G, Ronconi V, Lucarelli G, et al. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 2006; 24:737.</a></li><li><a class="nounderline abstract_t">Agharazii M, Douville P, Grose JH, Lebel M. Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension 2001; 37:1440.</a></li><li><a class="nounderline abstract_t">McKenna TJ, Sequeira SJ, Heffernan A, et al. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab 1991; 73:952.</a></li><li><a class="nounderline abstract_t">Gallay BJ, Ahmad S, Xu L, et al. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37:699.</a></li><li><a class="nounderline abstract_t">Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 2007; 66:607.</a></li><li><a class="nounderline abstract_t">Calhoun DA, Nishizaka MK, Zaman MA, et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40:892.</a></li><li><a class="nounderline abstract_t">Ahmed AH, Gordon RD, Taylor P, et al. Effect of atenolol on aldosterone/renin ratio calculated by both plasma Renin activity and direct Renin concentration in healthy male volunteers. J Clin Endocrinol Metab 2010; 95:3201.</a></li><li><a class="nounderline abstract_t">Fischer E, Beuschlein F, Bidlingmaier M, Reincke M. Commentary on the Endocrine Society Practice Guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism. Rev Endocr Metab Disord 2011; 12:43.</a></li><li><a class="nounderline abstract_t">Haab F, Duclos JM, Guyenne T, et al. Renin secreting tumors: diagnosis, conservative surgical approach and long-term results. J Urol 1995; 153:1781.</a></li><li><a class="nounderline abstract_t">Aron DC, Raff H, Findling JW. Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1997; 82:1780.</a></li><li><a class="nounderline abstract_t">Young DB. Quantitative analysis of aldosterone's role in potassium regulation. Am J Physiol 1988; 255:F811.</a></li><li><a class="nounderline abstract_t">Umakoshi H, Sakamoto R, Matsuda Y, et al. Role of Aldosterone and Potassium Levels in Sparing Confirmatory Tests in Primary Aldosteronism. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Holland OB, Brown H, Kuhnert L, et al. Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension 1984; 6:717.</a></li><li><a class="nounderline abstract_t">Stowasser M, Ahmed AH, Cowley D, et al. Comparison of Seated With Recumbent Saline Suppression Testing for the Diagnosis of Primary Aldosteronism. J Clin Endocrinol Metab 2018; 103:4113.</a></li><li><a class="nounderline abstract_t">Ahmed AH, Cowley D, Wolley M, et al. Seated saline suppression testing for the diagnosis of primary aldosteronism: a preliminary study. J Clin Endocrinol Metab 2014; 99:2745.</a></li><li><a class="nounderline abstract_t">Choi M, Scholl UI, Yue P, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011; 331:768.</a></li><li><a class="nounderline abstract_t">Fernandes-Rosa FL, Williams TA, Riester A, et al. Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. Hypertension 2014; 64:354.</a></li><li><a class="nounderline abstract_t">Prada ETA, Burrello J, Reincke M, Williams TA. Old and New Concepts in the Molecular Pathogenesis of Primary Aldosteronism. Hypertension 2017; 70:875.</a></li><li><a class="nounderline abstract_t">Nanba K, Omata K, Else T, et al. Targeted Molecular Characterization of Aldosterone-Producing Adenomas in White Americans. J Clin Endocrinol Metab 2018; 103:3869.</a></li><li><a class="nounderline abstract_t">Boulkroun S, Samson-Couterie B, Dzib JF, et al. Adrenal cortex remodeling and functional zona glomerulosa hyperplasia in primary aldosteronism. Hypertension 2010; 56:885.</a></li><li><a class="nounderline abstract_t">Fernandes-Rosa F, Giscos-Duricz I, Amar L, et al. Genetic abnormalities in lateralized multinodular primary aldosteronism. J Hypertens 2015; 33:e215.</a></li><li><a class="nounderline abstract_t">Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3266.</a></li><li><a class="nounderline abstract_t">Sheaves R, Goldin J, Reznek RH, et al. Relative value of computed tomography scanning and venous sampling in establishing the cause of primary hyperaldosteronism. Eur J Endocrinol 1996; 134:308.</a></li><li><a class="nounderline abstract_t">Gleason PE, Weinberger MH, Pratt JH, et al. Evaluation of diagnostic tests in the differential diagnosis of primary aldosteronism: unilateral adenoma versus bilateral micronodular hyperplasia. J Urol 1993; 150:1365.</a></li><li><a class="nounderline abstract_t">Radin DR, Manoogian C, Nadler JL. Diagnosis of primary hyperaldosteronism: importance of correlating CT findings with endocrinologic studies. AJR Am J Roentgenol 1992; 158:553.</a></li><li><a class="nounderline abstract_t">Doppman JL, Gill JR Jr, Miller DL, et al. Distinction between hyperaldosteronism due to bilateral hyperplasia and unilateral aldosteronoma: reliability of CT. Radiology 1992; 184:677.</a></li><li><a class="nounderline abstract_t">Harper R, Ferrett CG, McKnight JA, et al. Accuracy of CT scanning and adrenal vein sampling in the pre-operative localization of aldosterone-secreting adrenal adenomas. QJM 1999; 92:643.</a></li><li><a class="nounderline abstract_t">Lim V, Guo Q, Grant CS, et al. Accuracy of adrenal imaging and adrenal venous sampling in predicting surgical cure of primary aldosteronism. J Clin Endocrinol Metab 2014; 99:2712.</a></li><li><a class="nounderline abstract_t">Magill SB, Raff H, Shaker JL, et al. Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J Clin Endocrinol Metab 2001; 86:1066.</a></li><li><a class="nounderline abstract_t">Young WF, Stanson AW, Thompson GB, et al. Role for adrenal venous sampling in primary aldosteronism. Surgery 2004; 136:1227.</a></li><li><a class="nounderline abstract_t">Kempers MJ, Lenders JW, van Outheusden L, et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med 2009; 151:329.</a></li><li><a class="nounderline abstract_t">Nanba AT, Nanba K, Byrd JB, et al. Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism. Clin Endocrinol (Oxf) 2017; 87:665.</a></li><li><a class="nounderline abstract_t">Rossi GP, Auchus RJ, Brown M, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension 2014; 63:151.</a></li><li><a class="nounderline abstract_t">Doppman JL, Gill JR Jr. Hyperaldosteronism: sampling the adrenal veins. Radiology 1996; 198:309.</a></li><li><a class="nounderline abstract_t">Rossi GP, Sacchetto A, Chiesura-Corona M, et al. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 2001; 86:1083.</a></li><li><a class="nounderline abstract_t">Rossi GP, Pitter G, Bernante P, et al. Adrenal vein sampling for primary aldosteronism: the assessment of selectivity and lateralization of aldosterone excess baseline and after adrenocorticotropic hormone (ACTH) stimulation. J Hypertens 2008; 26:989.</a></li><li><a class="nounderline abstract_t">Young WF, Stanson AW. What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism? Clin Endocrinol (Oxf) 2009; 70:14.</a></li><li><a class="nounderline abstract_t">Daunt N. Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics 2005; 25 Suppl 1:S143.</a></li><li><a class="nounderline abstract_t">Nwariaku FE, Miller BS, Auchus R, et al. Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome. Arch Surg 2006; 141:497.</a></li><li><a class="nounderline abstract_t">Monticone S, Satoh F, Dietz AS, et al. Clinical Management and Outcomes of Adrenal Hemorrhage Following Adrenal Vein Sampling in Primary Aldosteronism. Hypertension 2016; 67:146.</a></li><li><a class="nounderline abstract_t">Young WF Jr. Primary aldosteronism--one picture is not worth a thousand words. Ann Intern Med 2009; 151:357.</a></li><li><a class="nounderline abstract_t">El Ghorayeb N, Mazzuco TL, Bourdeau I, et al. Basal and Post-ACTH Aldosterone and Its Ratios Are Useful During Adrenal Vein Sampling in Primary Aldosteronism. J Clin Endocrinol Metab 2016; 101:1826.</a></li><li><a class="nounderline abstract_t">Yang S, Du Z, Zhang X, et al. Corticotropin Stimulation in Adrenal Venous Sampling for Patients With Primary Aldosteronism: The ADOPA Randomized Clinical Trial. JAMA Netw Open 2023; 6:e2338209.</a></li><li><a class="nounderline abstract_t">Abdelhamid S, Müller-Lobeck H, Pahl S, et al. Prevalence of adrenal and extra-adrenal Conn syndrome in hypertensive patients. Arch Intern Med 1996; 156:1190.</a></li><li><a class="nounderline abstract_t">Biglieri EG. Spectrum of mineralocorticoid hypertension. Hypertension 1991; 17:251.</a></li><li><a class="nounderline abstract_t">Phillips JL, Walther MM, Pezzullo JC, et al. Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab 2000; 85:4526.</a></li><li><a class="nounderline abstract_t">Young WF Jr, Klee GG. Primary aldosteronism. Diagnostic evaluation. Endocrinol Metab Clin North Am 1988; 17:367.</a></li><li><a class="nounderline abstract_t">Nomura K, Kusakabe K, Maki M, et al. Iodomethylnorcholesterol uptake in an aldosteronoma shown by dexamethasone-suppression scintigraphy: relationship to adenoma size and functional activity. J Clin Endocrinol Metab 1990; 71:825.</a></li><li><a class="nounderline abstract_t">Scholl UI, Stölting G, Schewe J, et al. CLCN2 chloride channel mutations in familial hyperaldosteronism type II. Nat Genet 2018; 50:349.</a></li><li><a class="nounderline abstract_t">Wu WC, Peng KY, Lu JY, et al. Cortisol-producing adenoma-related somatic mutations in unilateral primary aldosteronism with concurrent autonomous cortisol secretion: their prevalence and clinical characteristics. Eur J Endocrinol 2022; 187:519.</a></li><li><a class="nounderline abstract_t">Riester A, Reincke M. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy. Eur J Endocrinol 2015; 172:R23.</a></li><li><a class="nounderline abstract_t">Eschler DC, Kogekar N, Pessah-Pollack R. Management of adrenal tumors in pregnancy. Endocrinol Metab Clin North Am 2015; 44:381.</a></li><li><a class="nounderline abstract_t">Monticone S, Auchus RJ, Rainey WE. Adrenal disorders in pregnancy. Nat Rev Endocrinol 2012; 8:668.</a></li><li><a class="nounderline abstract_t">Krysiak R, Samborek M, Stojko R. Primary aldosteronism in pregnancy. Acta Clin Belg 2012; 67:130.</a></li><li><a class="nounderline abstract_t">Zelinka T, Petrák O, Rosa J, et al. Primary Aldosteronism and Pregnancy. Kidney Blood Press Res 2020; 45:275.</a></li><li><a class="nounderline abstract_t">Eguchi K, Hoshide S, Nagashima S, et al. An adverse pregnancy-associated outcome due to overlooked primary aldosteronism. Intern Med 2014; 53:2499.</a></li></ol></div><div id="topicVersionRevision">Topic 138 Version 55.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15001583" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18539224" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27172433" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28385310" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26934393" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32449886" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7913162" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Mineralocorticoid hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10218547" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Mineralocorticoid hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16932426" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Primary aldosteronism: diagnostic and treatment strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6262353" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Normotensive primary aldosteronism: report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29129575" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17161262" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10946893" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30027227" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30255616" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Diagnosis and treatment of primary aldosteronism: practical clinical perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33370170" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Testing for Primary Aldosteronism and Mineralocorticoid Receptor Antagonist Use Among U.S. Veterans : A Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32008436" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Screening Rates for Primary Aldosteronism in Resistant Hypertension: A Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30415872" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Keeping primary aldosteronism in mind: Deficiencies in screening at-risk hypertensives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34657442" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Screening Rates for Primary Aldosteronism Among Individuals With Hypertension Plus Hypokalemia: A Population-Based Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26372319" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical validation for the aldosterone-to-renin ratio and aldosterone suppression testing using simultaneous fully automated chemiluminescence immunoassays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8379804" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The diagnosis of primary aldosteronism and separation of two major subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36179243" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Aldosterone, Renin, and Aldosterone-to-Renin Ratio Variability in Screening for Primary Aldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36413507" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Intra-individual Variability of Serum Aldosterone and Implications for Primary Aldosteronism Screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7978702" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Diagnosis and treatment of primary hyperaldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11560297" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Validity of the aldosterone-renin ratio used to screen for primary aldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11549664" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Performance of the basal aldosterone to renin ratio and of the renin stimulation test by furosemide and upright posture in screening for aldosterone-producing adenoma in low renin hypertensives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16531803" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11408392" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Captopril suppression versus salt loading in confirming primary aldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1939533" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11273868" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17492946" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Primary aldosteronism: renaissance of a syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12468575" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hyperaldosteronism among black and white subjects with resistant hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20427490" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effect of atenolol on aldosterone/renin ratio calculated by both plasma Renin activity and direct Renin concentration in healthy male volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21331645" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Commentary on the Endocrine Society Practice Guidelines: Consequences of adjustment of antihypertensive medication in screening of primary aldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7752315" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Renin secreting tumors: diagnosis, conservative surgical approach and long-term results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9177382" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3056039" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Quantitative analysis of aldosterone's role in potassium regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31665338" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Role of Aldosterone and Potassium Levels in Sparing Confirmatory Tests in Primary Aldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6389337" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Further evaluation of saline infusion for the diagnosis of primary aldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30239841" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Comparison of Seated With Recumbent Saline Suppression Testing for the Diagnosis of Primary Aldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24762111" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Seated saline suppression testing for the diagnosis of primary aldosteronism: a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21311022" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24866132" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28974569" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Old and New Concepts in the Molecular Pathogenesis of Primary Aldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30085035" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Targeted Molecular Characterization of Aldosterone-Producing Adenomas in White Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20937967" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Adrenal cortex remodeling and functional zona glomerulosa hyperplasia in primary aldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Genetic abnormalities in lateralized multinodular primary aldosteronism</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18552288" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8616527" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Relative value of computed tomography scanning and venous sampling in establishing the cause of primary hyperaldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8411401" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Evaluation of diagnostic tests in the differential diagnosis of primary aldosteronism: unilateral adenoma versus bilateral micronodular hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1738993" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Diagnosis of primary hyperaldosteronism: importance of correlating CT findings with endocrinologic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1509049" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Distinction between hyperaldosteronism due to bilateral hyperplasia and unilateral aldosteronoma: reliability of CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10542304" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Accuracy of CT scanning and adrenal vein sampling in the pre-operative localization of aldosterone-secreting adrenal adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24796926" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Accuracy of adrenal imaging and adrenal venous sampling in predicting surgical cure of primary aldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11238487" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15657580" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Role for adrenal venous sampling in primary aldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19721021" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28787766" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24218436" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8596821" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Hyperaldosteronism: sampling the adrenal veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11238490" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18398342" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Adrenal vein sampling for primary aldosteronism: the assessment of selectivity and lateralization of aldosterone excess baseline and after adrenocorticotropic hormone (ACTH) stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19128364" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16227488" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Adrenal vein sampling: how to make it quick, easy, and successful.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16702522" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26573704" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Clinical Management and Outcomes of Adrenal Hemorrhage Following Adrenal Vein Sampling in Primary Aldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19721025" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Primary aldosteronism--one picture is not worth a thousand words.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26918291" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Basal and Post-ACTH Aldosterone and Its Ratios Are Useful During Adrenal Vein Sampling in Primary Aldosteronism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37870836" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Corticotropin Stimulation in Adrenal Venous Sampling for Patients With Primary Aldosteronism: The ADOPA Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8639013" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Prevalence of adrenal and extra-adrenal Conn syndrome in hypertensive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1846843" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Spectrum of mineralocorticoid hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11134103" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3042391" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Primary aldosteronism. Diagnostic evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2401712" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Iodomethylnorcholesterol uptake in an aldosteronoma shown by dexamethasone-suppression scintigraphy: relationship to adenoma size and functional activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29403011" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : CLCN2 chloride channel mutations in familial hyperaldosteronism type II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35900323" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Cortisol-producing adenoma-related somatic mutations in unilateral primary aldosteronism with concurrent autonomous cortisol secretion: their prevalence and clinical characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25163723" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26038207" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Management of adrenal tumors in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22965163" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Adrenal disorders in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22712170" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Primary aldosteronism in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32114578" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Primary Aldosteronism and Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25366010" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : An adverse pregnancy-associated outcome due to overlooked primary aldosteronism.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
